Leerink Partnrs Brokers Raise Earnings Estimates for BMRN

BioMarin Pharmaceutical Inc. (NASDAQ:BMRN) – Research analysts at Leerink Partnrs raised their Q2 2025 earnings estimates for shares of BioMarin Pharmaceutical in a research note issued on Wednesday, February 19th. Leerink Partnrs analyst J. Schwartz now forecasts that the biotechnology company will post earnings per share of $0.94 for the quarter, up from their prior forecast of $0.81. The consensus estimate for BioMarin Pharmaceutical’s current full-year earnings is $3.15 per share.

Several other research analysts also recently commented on the stock. Piper Sandler lifted their target price on shares of BioMarin Pharmaceutical from $122.00 to $126.00 and gave the stock an “overweight” rating in a research note on Thursday, February 20th. Royal Bank of Canada restated a “sector perform” rating and issued a $70.00 price objective on shares of BioMarin Pharmaceutical in a research report on Thursday, February 20th. JPMorgan Chase & Co. dropped their target price on shares of BioMarin Pharmaceutical from $110.00 to $109.00 and set an “overweight” rating for the company in a report on Wednesday, October 30th. Scotiabank boosted their price target on BioMarin Pharmaceutical from $78.00 to $80.00 and gave the company a “sector perform” rating in a report on Thursday, February 20th. Finally, UBS Group upped their price target on BioMarin Pharmaceutical from $109.00 to $113.00 and gave the company a “buy” rating in a research report on Thursday, February 20th. Seven analysts have rated the stock with a hold rating, seventeen have given a buy rating and one has assigned a strong buy rating to the company’s stock. Based on data from MarketBeat, the company currently has an average rating of “Moderate Buy” and an average target price of $94.00.

BioMarin Pharmaceutical Price Performance

BMRN opened at $71.17 on Monday. The company has a debt-to-equity ratio of 0.11, a current ratio of 5.33 and a quick ratio of 2.62. The stock’s 50 day simple moving average is $65.03 and its 200 day simple moving average is $70.48. The firm has a market cap of $13.56 billion, a price-to-earnings ratio of 32.35, a PEG ratio of 0.61 and a beta of 0.28. BioMarin Pharmaceutical has a 1 year low of $60.63 and a 1 year high of $94.85.

BioMarin Pharmaceutical (NASDAQ:BMRN) last announced its quarterly earnings data on Wednesday, February 19th. The biotechnology company reported $0.72 earnings per share (EPS) for the quarter, beating analysts’ consensus estimates of $0.54 by $0.18. BioMarin Pharmaceutical had a return on equity of 9.91% and a net margin of 14.96%. The firm had revenue of $747.31 million for the quarter, compared to analysts’ expectations of $711.05 million.

Insider Activity

In related news, CAO Erin Burkhart sold 1,344 shares of the company’s stock in a transaction that occurred on Monday, February 24th. The stock was sold at an average price of $68.38, for a total value of $91,902.72. Following the sale, the chief accounting officer now owns 13,105 shares in the company, valued at $896,119.90. This represents a 9.30 % decrease in their position. The transaction was disclosed in a filing with the SEC, which is available at this hyperlink. Company insiders own 1.85% of the company’s stock.

Institutional Investors Weigh In On BioMarin Pharmaceutical

Several hedge funds have recently added to or reduced their stakes in the stock. Polar Asset Management Partners Inc. purchased a new stake in BioMarin Pharmaceutical during the 4th quarter valued at about $979,000. Mackenzie Financial Corp lifted its stake in shares of BioMarin Pharmaceutical by 203.4% in the fourth quarter. Mackenzie Financial Corp now owns 220,661 shares of the biotechnology company’s stock worth $14,504,000 after buying an additional 147,927 shares in the last quarter. Forum Financial Management LP purchased a new stake in shares of BioMarin Pharmaceutical during the fourth quarter valued at approximately $298,000. Toronto Dominion Bank increased its position in shares of BioMarin Pharmaceutical by 3.8% during the fourth quarter. Toronto Dominion Bank now owns 24,862 shares of the biotechnology company’s stock valued at $1,634,000 after acquiring an additional 920 shares in the last quarter. Finally, GF Fund Management CO. LTD. bought a new stake in shares of BioMarin Pharmaceutical during the fourth quarter valued at approximately $263,000. 98.71% of the stock is owned by institutional investors.

BioMarin Pharmaceutical Company Profile

BioMarin Pharmaceutical Inc develops and commercializes therapies for people with serious and life-threatening rare diseases and medical conditions. Its commercial products include Vimizim, an enzyme replacement therapy for the treatment of mucopolysaccharidosis (MPS) IV type A, a lysosomal storage disorder; Naglazyme, a recombinant form of N-acetylgalactosamine 4-sulfatase for patients with MPS VI; and Kuvan, a proprietary synthetic oral form of 6R-BH4 that is used to treat patients with phenylketonuria (PKU), an inherited metabolic disease.